Treatment of acute respiratory infections in pregnant women

• Valentina V. Malinovskaya
• Igor I. Baranov
• Evgenia N. Vyzhlova
• Shuvalov Alexander N.

Abstract

Acute respiratory viral infections (ARVI) is one of the main reasons for hospitalization of pregnant women, representing a poor risk group for unfavourable course of acute respiratory viral infections.

Material and methods. 330 cases of hospitalization of pregnant women with acute respiratory viral infections of various etiologies who were hospitalized at the Moscow Infectious Clinical Hospital # 1 were analyzed. AH pregnant women were divided into 2 groups: antiviral drug treatment group and symptomatic therapy group.

Results and discussion. In the antiviral therapy group fetoplacental insufficiency (FPF), threatened miscarriage, hypamnion and intrauterine growth retardation were significantly less likely to develop (p<0.05). Also in this group chronic pathology recrudescence incidence significantly reduced. Moreover, there was a significantly higher frequency of small for date (<2500 g) and premature infants among newborns from mothers who received only symptomatic therapy for acute respiratory viral infections.

Conclusion. Recombinant interferon alpha-2b administration in treatment of acute respiratory viral infections in pregnant women avoid the necessity for additional prescription of antibacterial drugs during pregnancy.

Keywords:ARVI, pregnancy, treatment, pregnancy complications, preterm newborns, recombinant interferon alfa-2b

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)